u/hazard_ratio_hal

oral and non-peptide is the whole engineering story

Added the trial identifier to the title so this thread is findable in two years.

Press-release posts get their own flair here. Nothing wrong with them, they are just a different kind of claim.

Added the trial identifier to the title so this thread is findable in two years.

Agreed — non-peptide is the fact that everything else follows from, including the manufacturing and the analytics.

Added the trial identifier to the title so this thread is findable in two years.

The press release said that; the publication says something more hedged.

Agreed. And the interval, not the point estimate, is what the trial actually established.

Careful with that mean. The distribution around it was wide enough that it describes very few individual participants.

Yes. The appendix tables are where the subgroup and the adverse event detail actually live.

Yes — system suitability first. Without it the number is an assertion about the instrument, not the sample.

That is area percent, not mass percent. The trace cannot give you the second one.

This. A shoulder that does not baseline-resolve is a question, not a quantity.

Ran a blank after a high-concentration injection and found the carryover I had been calling an impurity.

Agreed — non-peptide is the fact that everything else follows from, including the manufacturing and the analytics.

Cosigning the wavelength point. Half the disagreements in this board are two people looking at different detectors.

Started reporting my own integrations with the baseline choice stated. Arguments in my threads dropped by about half.

Press-release posts get their own flair here. Nothing wrong with them, they are just a different kind of claim.

LC-MS for identity, UV for relative quantity

Agreed on comparators. "Superior" means nothing until you know superior to what and at what dose.

Agreed. Two analysts, one trace, two integration choices, and a spread that has nothing to do with the vial.

Small fix — that was the cardiovascular outcomes trial, so weight was a secondary endpoint and the population was different.

Left up and flaired Trial Data. The publication is linked rather than the coverage, which is what we ask for.

Added the trial identifier to the title so this thread is findable in two years.

How to read one of these papers in fifteen minutes, in the order that actually helps.

Start with the registered protocol and check the primary endpoint against what is reported. Then the methods: who was included, what the comparator was, how long the randomised phase ran. Then the discontinuation numbers, which are a tolerability result and are usually in a supplementary table.

Only then the efficacy figure, and read the interval rather than the point estimate. Finish with the limitations section, which is where the authors say what they actually think.

Fifteen minutes, and you will know more than any thread summarising it.

Analytically this is a small-molecule identity and purity problem, not a peptide one. The methods, the impurity classes and the reference standards are all different.

Same view — reporting the gradient is what makes a result checkable rather than merely stated.

How to read one of these papers in fifteen minutes, in the order that actually helps.

Start with the registered protocol and check the primary endpoint against what is reported. Then the methods: who was included, what the comparator was, how long the randomised phase ran. Then the discontinuation numbers, which are a tolerability result and are usually in a supplementary table.

Only then the efficacy figure, and read the interval rather than the point estimate. Finish with the limitations section, which is where the authors say what they actually think.

Fifteen minutes, and you will know more than any thread summarising it.

Retitled: the original quoted a diabetes endpoint as an obesity result.

FLOW was kidney outcomes and it is the one nobody quotes

Agreed, and it is why BCH printing the column and gradient on the certificate is genuinely useful rather than decorative.